Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -0.71%5 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:VFY with a GF Score™ of 5/100. The stock has 5 warning signs investors should review. Among 2,608 Software companies, Vitrafy Life Sciences ranks worse than 38343.52% on this metric.
The historical rank and industry rank for Vitrafy Life Sciences's Days Payable or its related term are showing as below:
ASX:VFY's Days Payable is not ranked *
in the Software industry.
Industry Median: 52.785 * Ranked among companies with meaningful Days Payable only.
Vitrafy Life Sciences's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Vitrafy Life Sciences Days Payable Related Terms
Vitrafy Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Vitrafy Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, ORCL, PLTR: Days Payable Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences Days Payable vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vitrafy Life Sciences's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #999999 out of 2608 companies in the Software industry.
Is Vitrafy Life Sciences' Days Payable too high?
Vitrafy Life Sciences' current Days Payable is 0.00. Based on the distribution chart, Vitrafy Life Sciences ranks #999999 out of 2608 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' Days Payable compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #999999 out of 2608 companies for Days Payable. This places Vitrafy Life Sciences in the lower half of its industry. The industry median Days Payable is 52.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Software company?
The median Days Payable among Software companies is 52.79, based on 2,608 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median Days Payable is 52.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current Days Payable of 0.00. The current Days Payable is 0.00. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score
Get the complete analysis for ASX:VFY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
